JNJ

Johnson & Johnson First Quarter 2013 Earnings Meeting and Webcast

[at noodls] – Webcasts & Presentations Safe Harbor Statement These presentations contain forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. You are cautioned not … moreView todays social media effects on JNJView the latest stocks trending across Twitter. Click to view dashboardSee who Johnson is hiring next, click here to view […]

“Healthy Vision™ With Dr. Val Jones” Show Now Available On All About Vision®

[at noodls] – JACKSONVILLE, Fla. (February 26, 2013) — VISTAKON®, Division of Johnson & Johnson Vision Care, Inc., today announced its Healthy Visionâ„¢ with Dr. Val Jones podcast series is now available on AllAboutVision.com. … moreView todays social media effects on JNJView the latest stocks trending across Twitter. Click to view dashboardSee who Johnson is hiring next, click here to […]

Johnson & Johnson to Participate in 2013 Leerink Swann Global Health Care Conference

[at noodls] – New Brunswick, NJ (Feb. 6, 2013) — Johnson & Johnson (NYSE: JNJ) will participate in the 2013 Leerink Swann Global Health Care Conference on Wednesday, Feb. 13, at The Waldorf Astoria in New York, NY. … moreView todays social media effects on JNJView the latest stocks trending across Twitter. Click to view dashboardSee who Johnson is hiring […]

Johnson & Johnson to Host Analyst Meeting to Discuss Fourth-Quarter/Full-Year 2012 Financial Results and Medical Devices and Diagnostics Review

[at noodls] – New Brunswick, NJ (Dec. 21, 2012) – Johnson & Johnson will host an analyst meeting at 8:30 a.m. (Eastern Time) on Tuesday, Jan. 22, to discuss fourth-quarter and full-year 2012 financial results. The meeting … moreView todays social media effects on JNJView the latest stocks trending across Twitter. Click to view dashboardSee who Johnson is hiring next, […]

Max Reinhardt Named Worldwide President Of Depuy Synthes Spine

[at noodls] – RAYNHAM, MA – DECEMBER 12, 2012 – The DePuy Synthes Companies of Johnson & Johnson announced today that Max Reinhardt has been named Worldwide President of DePuy Synthes Spine, a global leader in spinal … moreView todays social media effects on JNJView the latest stocks trending across Twitter. Click to view dashboardSee who Johnson is hiring next, […]

Janssen Announces Intent Not to Enforce Patents for Darunavir in Resource-Limited Settings

[at noodls] – Policy Aims to Support a Sustainable Supply of Medically Acceptable Generic Darunavir in Sub-Saharan Africa (SSA) and Least Developed Countries (LDC) November 29, 2012 – The Janssen Pharmaceutical Companies … moreView todays social media effects on JNJView the latest stocks trending across Twitter. Click to view dashboard […]

INCRAFTâ„¢ AAA Stent-Graft System One-Year Follow-Up Data Presented At 2012 Veith Symposium

[at noodls] – Study Demonstrates Safety and Efficacy of New Customizable and Ultra-Low Profile Stent-Graft System for the Treatment of Abdominal Aortic Aneurysms Bridgewater, New Jersey – November 17, 2012 – Cordis … moreView todays social media effects on JNJView the latest stocks trending across Twitter. Click to view dashboard […]

Johnson & Johnson to Participate in Credit Suisse 2012 Healthcare Conference

[at noodls] – Safe Harbor Statement These presentations contain forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. You are cautioned not to rely on these forward-looking … moreView todays social media effects on JNJView the latest stocks trending across Twitter. Click to view dashboard […]

Janssen and Johnson & Johnson to Provide Webcast Presentation of Immunology Pivotal Phase 3 Data Being Presented at the American College of Rheumatology Annual Meeting

[at noodls] – Safe Harbor Statement These presentations contain forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. You are cautioned not to rely on these forward-looking … moreView todays social media effects on JNJView the latest stocks trending across Twitter. Click to view dashboard […]

PropThink: Lexicon’s Stock Offering; In Biotech, it’s Raise When You Can

[ACN Newswire] – By Jake KingDespite a stash of cash and liquid investments, Lexicon Pharmaceuticals (NASDAQ:LXRX) caught investors off guard two weeks ago by initiating a capital raise. The company had more than $225M … moreView todays social media effects on JNJView the latest stocks trending across Twitter. Click to view dashboard […]